Drugs / Serlopitant
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 29 trials · 3 met primary · 2 missed | ||||||
| Phase 2 | NCT03841331 | Jan → Dec 2019 | — | Vyne Therapeutics Inc. | Completed | Missed primary |
| Phase 2 | NCT03343639 | Nov 2017 → Oct 2018 | psoriasis | Vyne Therapeutics Inc. | Completed | Met primary |
| Phase 2 | NCT03282591 | Oct 2017 → Aug 2018 | upper respiratory tract disorder | Vyne Therapeutics Inc. | Completed | Missed primary |
| Phase 2 | NCT02975206 | Nov 2016 → Jan 2018 | atopic eczema | Vyne Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02975271 | Nov 2016 → Jan 2017 | — | Vyne Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02654483 | Aug 2016 → Jun 2018 | epidermolysis bullosa | Jean Yuh Tang | Completed | No outcome recorded |
| Phase 2 | NCT01951274 | Oct 2013 → Dec 2014 | — | Vyne Therapeutics Inc. | Completed | Met primary |
| Phase 2 | NCT00835718 | Feb 2009 → Mar 2010 | alcohol dependence | Vyne Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00290563 | Feb 2006 → Aug 2007 | overactive bladder | Vyne Therapeutics Inc. | Completed | Met primary |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT03677401 | Aug 2018 → Jan 2020 | prurigo, prurigo nodularis | Vyne Therapeutics Inc. | Completed | Missed primary |
| Phase 3 | NCT03546816 | May 2018 → Jan 2020 | prurigo nodularis | Vyne Therapeutics Inc. | Completed | Missed primary |
| Phase 3 | NCT03540160 | Mar 2018 → Apr 2020 | atopic eczema, prurigo nodularis, psoriasis | Vyne Therapeutics Inc. | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03836001 Comparator | Apr 2019 → Dec 2021 | epidermolysis bullosa | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT02196324 Comparator | Jul 2014 → May 2016 | prurigo nodularis | Vyne Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Serlopitant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03841331 ↗ |
| Known as | MK0594 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00835718 ↗ |
| Known as | VPD-737 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01951274 ↗ |
| Action | Inhibit | “Neurokinin 1 receptor antagonist” CHEMBL447955 ↗1“neurokinin-1 receptor antagonist” PMID 20639026 ↗ Jun 2010 |
| Modality | Small molecule | “Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist.” NCT03836001 ↗ |
| Route | Oral | “MK0594 5 mg tablets taken orally once daily for 12 weeks.” NCT00835718 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL447955 ↗ |